Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Exelixis

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1994-01-01

Employees: 1.3K

Market Cap: $7.3B

Website: http://www.exelixis.com

Introduction: Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Clinical Trials

Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)

Phase 1

Recruiting

Conditions: Hepatic Impairment
Moderate Hepatic Impairment

Interventions: Drug: Zanzalintinib

First Posted Date: 2025-05-08

Last Posted Date: 2025-06-22

Lead Sponsor: Exelixis

Target Recruit Count: 20

Registration Number: NCT06962332

Locations: 🇺🇸
Exelixis Clinical Site #1, Orlando, Florida, United States
🇺🇸
Exelixis Clinical Site #2, San Antonio, Texas, United States

A Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumor
Metastatic Solid Tumor
Advanced Solid Tumor
Immune Sensitive Tumor

Interventions: Biological: XB628

First Posted Date: 2025-04-30

Last Posted Date: 2025-06-15

Lead Sponsor: Exelixis

Target Recruit Count: 75

Registration Number: NCT06952010

Locations: 🇺🇸
Exelixis Clinical Site #1, Hickory, North Carolina, United States
🇺🇸
Exelixis Clinical Site #2, San Antonio, Texas, United States

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

Phase 2

Recruiting

Conditions: Pancreatic Neuroendocrine Tumor (pNET)
Extra-Pancreatic Neuroendocrine Tumor (epNET)

Interventions: Drug: Zanzalintinib
Drug: Everolimus

First Posted Date: 2025-04-24

Last Posted Date: 2025-06-22

Lead Sponsor: Exelixis

Target Recruit Count: 440

Registration Number: NCT06943755

Locations: 🇵🇷
Exelixis Clinical Site #2, San Juan, Puerto Rico
🇺🇸
Exelixis Clinical Site #1, Grand Rapids, Michigan, United States

A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1

Terminated

Conditions: Solid Cancers
Solid Tumor Cancer
Solid Tumor Malignancy
Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)
Metastatic Solid Tumor
Locally Advanced Solid Tumor
Urothelial Cancer of Renal Pelvis

Interventions: Drug: XL495
Drug: ADC cytotoxic agents

First Posted Date: 2024-10-08

Last Posted Date: 2025-06-25

Lead Sponsor: Exelixis

Target Recruit Count: 9

Registration Number: NCT06630247

Locations: 🇺🇸
Exelixis Clinical Site #4, Denver, Colorado, United States
🇺🇸
Exelixis Clinical Site #9, New Haven, Connecticut, United States
🇺🇸
Exelixis Clinical Site #8, Washington, District of Columbia, United States

and more 17 locations

Study of XB010 in Subjects With Solid Tumors

Phase 1

Recruiting

Conditions: Locally Advanced or Metastatic Solid Tumors
Esophageal Squamous Cell Cancer
Head and Neck Squamous Cell Cancer
NSCLC (Non-small Cell Lung Cancer)
Hormone-receptor-positive Breast Cancer
Triple Negative Breast Cancer (TNBC)

Interventions: Drug: XB010
Drug: Pembrolizumab

First Posted Date: 2024-08-09

Last Posted Date: 2025-03-14

Lead Sponsor: Exelixis

Target Recruit Count: 396

Registration Number: NCT06545331

Locations: 🇺🇸
Exelixis Clinical Site #7, Dallas, Texas, United States
🇺🇸
Exelixis Clinical Site #8, Houston, Texas, United States
🇺🇸
Exelixis Clinical Site #4, Duarte, California, United States

and more 5 locations

Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)

Phase 1

Terminated

Conditions: Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors

Interventions: Drug: zanzalintinib
Drug: AB521
Biological: Nivolumab

First Posted Date: 2024-01-05

Last Posted Date: 2025-06-12

Lead Sponsor: Exelixis

Target Recruit Count: 140

Registration Number: NCT06191796

Locations: 🇺🇸
Exelixis Site #8, Los Angeles, California, United States
🇺🇸
Exelixis Site #9, Miami, Florida, United States
🇺🇸
Exelixis Clinical Site #1, Orlando, Florida, United States

and more 11 locations

Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 2

Recruiting

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Zanzalintinib-matched Placebo
Drug: Zanzalintinib
Biological: Pembrolizumab

First Posted Date: 2023-10-13

Last Posted Date: 2025-01-31

Lead Sponsor: Exelixis

Target Recruit Count: 600

Registration Number: NCT06082167

Locations: 🇦🇹
Exelixis Clinical Site #166, Vienna, Austria
🇩🇪
Exelixis Clinical Site #167, Giessen, Germany
🇲🇽
Exelixis Clinical Site #168, Guadalajara, Mexico

and more 165 locations

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: XL309 (ISM3091)
Drug: Olaparib

First Posted Date: 2023-07-06

Last Posted Date: 2025-03-13

Lead Sponsor: Exelixis

Target Recruit Count: 425

Registration Number: NCT05932862

Locations: 🇺🇸
Exelixis Clinical Site #12, Fountain Valley, California, United States
🇺🇸
Exelixis Clinical Site #15, Jacksonville, Florida, United States
🇺🇸
Exelixis Clinical Site #8, Orlando, Florida, United States

and more 13 locations

Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

Phase 3

Recruiting

Conditions: Non-Clear Cell Renal Cell Carcinoma

Interventions: Drug: Sunitinib Malate
Drug: XL092
Drug: Nivolumab

First Posted Date: 2023-01-10

Last Posted Date: 2024-12-17

Lead Sponsor: Exelixis

Target Recruit Count: 291

Registration Number: NCT05678673

Locations: 🇺🇸
Exelixis Clinical Site #164, Newport Beach, California, United States
🇺🇸
Exelixis Clinical Site #162, San Francisco, California, United States
🇺🇸
Exelixis Clinical Site #163, Aurora, Colorado, United States

and more 161 locations

Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer

Phase 3

Active, not recruiting

Conditions: Colorectal Cancer

Interventions: Drug: XL092
Drug: Regorafenib
Drug: Atezolizumab

First Posted Date: 2022-06-21

Last Posted Date: 2024-07-05

Lead Sponsor: Exelixis

Target Recruit Count: 874

Registration Number: NCT05425940

Locations: 🇺🇸
Exelixis Clinical Site #65, Jonesboro, Alabama, United States
🇺🇸
Exelixis Clinical Site #30, Phoenix, Arizona, United States
🇺🇸
Exelixis Clinical Site #70, Tucson, Arizona, United States

and more 130 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy